Medical device recalls Moderate risk

Dexcom Inc recalls Dexcom G5 Continuous Glucose Monitoring System The Dexcom G4 PLATINUM Continuous Glucose Monitoring System is a glucose…

Recall date
February 3, 2020
Source
U.S. Food & Drug Administration (FDA) — enforcement report
Recall number
Z-1561-2020
FDA classification
Class II
Brand / firm
Dexcom Inc
Sold / distributed
World-wide Distribution

Why it was recalled

The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems.

Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What was recalled

Dexcom G5 Continuous Glucose Monitoring System The Dexcom G4 PLATINUM Continuous Glucose Monitoring System is a glucose monitoring device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes.

Get recall alerts

Free email alert whenever Dexcom Inc has a new recall — straight from official government data. Unsubscribe anytime.

More recalls from: Dexcom Inc